Exosome Therapy

Based on the available evidence, exosome therapy is being investigated across multiple medical conditions, though the research is still in early stages. The current literature focuses primarily on engineering approaches and potential therapeutic applications rather than completed clinical outcomes.

Recent research has explored manufacturing and delivery methods for exosome-based treatments, with studies examining additive manufacturing techniques for producing and isolating these therapeutic vesicles. Neurological applications appear to be a major research focus, with investigations into exosome therapy for traumatic brain injury, ischemic stroke, and associated complications like auditory problems.

Stem cell-derived exosomes are receiving particular attention, with research examining their potential for treating ocular surface disorders and other conditions. Studies are also exploring the use of exosomes in neonatal health applications, though this work appears to be primarily systematic reviews rather than original clinical data.

The research includes investigations into cancer applications, examining exosomal biomarkers in non-small-cell lung cancer, and broader work on exosome nanotechnology for gene therapy applications.

However, most of these appear to be review articles, engineering studies, or early-stage research rather than completed clinical trials with patient outcomes data.

Clinical Trials

Several clinical trials are investigating exosome therapy, though most are in early phases:

Active/Recruiting Studies:

• A Phase 1/2 trial (NCT07510139) is testing umbilical cord mesenchymal stem cell-derived exosomes for premature ovarian insufficiency, currently in the active but not recruiting phase
• A Phase 1 study (NCT07065409) is recruiting patients to test iPSC-derived exosomes for Moyamoya disease
• Another Phase 1 trial (NCT07587047) is recruiting for lower back pain treatment

COVID-19 Applications:

• A Phase 2/3 trial (NCT05216562) examined exosome-MSC therapy for moderate COVID-19 patients, though the current status is unknown
• A completed Phase 2 study (NCT04493242) investigated extracellular vesicle infusion for COVID-19 associated ARDS, though results are not provided in the available evidence

The clinical trial evidence shows exosome therapy is being tested across diverse conditions, but most studies are still in Phase 1 or early Phase 2, indicating the field is in preliminary stages of human testing.

Important note: This information is for educational purposes only and should not be considered medical advice. Consult healthcare professionals for treatment decisions.